[go: up one dir, main page]

IN2009DN05758A - - Google Patents

Download PDF

Info

Publication number
IN2009DN05758A
IN2009DN05758A IN5758DEN2009A IN2009DN05758A IN 2009DN05758 A IN2009DN05758 A IN 2009DN05758A IN 5758DEN2009 A IN5758DEN2009 A IN 5758DEN2009A IN 2009DN05758 A IN2009DN05758 A IN 2009DN05758A
Authority
IN
India
Prior art keywords
antibodies
solubility
methods
stability
scfv
Prior art date
Application number
Inventor
Urech David
Borras Leonardo
Original Assignee
Esbatech Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esbatech Ag filed Critical Esbatech Ag
Publication of IN2009DN05758A publication Critical patent/IN2009DN05758A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention provides methods of using sequence based analysis and rational strategies to modify and improve the structural and biophysical properties of single chain antibodies (scFvs), including stability, solubility, and antigen binding affinity. These methods and strategies can be used individually or in combination. The methods of the present invention also include the use of a database comprising scFv sequences from an experimentally screened scFv library of antibodies that have been selected to have superior solubility and stability. The invention also provides methods of using the properties found for these selected antibodies in a general approach for reshaping scFv antibodies to improve stability and solubility properties of a single chain antibody fragment.
IN5758DEN2009 2007-03-12 2008-03-12 IN2009DN05758A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90636507P 2007-03-12 2007-03-12
PCT/EP2008/001958 WO2008110348A1 (en) 2007-03-12 2008-03-12 Sequence based engineering and optimization of single chain antibodies

Publications (1)

Publication Number Publication Date
IN2009DN05758A true IN2009DN05758A (en) 2015-07-24

Family

ID=39586970

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5758DEN2009 IN2009DN05758A (en) 2007-03-12 2008-03-12

Country Status (11)

Country Link
US (2) US8280711B2 (en)
EP (2) EP2118138A1 (en)
JP (1) JP5622397B2 (en)
CN (2) CN101668771B (en)
AU (1) AU2008226067B2 (en)
CA (1) CA2680564C (en)
IL (1) IL200710A (en)
IN (1) IN2009DN05758A (en)
NZ (1) NZ579594A (en)
RU (2) RU2009137582A (en)
WO (1) WO2008110348A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2009DN05758A (en) 2007-03-12 2015-07-24 Esbatech Ag
RU2010102064A (en) * 2007-06-25 2011-07-27 Эсбатек, Эн Элкон Биомедикал Рисёрч Юнит Ллк (Ch) METHOD OF DESIGNING BASED ON DETERMINATION OF SEQUENCES, METHOD OF OPTIMIZATION OF SINGLE-CHAIN ANTIBODIES
NZ581468A (en) 2007-06-25 2012-09-28 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies, and modified antibodies with improved functional properties
WO2009155725A1 (en) 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc Solubility optimization of immunobinders
DK2307454T3 (en) 2008-06-25 2017-04-24 Esbatech Alcon Biomed Res Unit Stable and soluble antibodies that inhibit VEGF
ES2677003T3 (en) 2008-06-25 2018-07-27 Esbatech, An Alcon Biomedical Research Unit Llc Humanization of rabbit antibodies using a universal antibody framework
CN102076716A (en) 2008-06-25 2011-05-25 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 Stable and soluble antibodies that inhibit TNFα
WO2010108154A2 (en) 2009-03-20 2010-09-23 Amgen Inc. Selective and potent peptide inhibitors of kv1.3
US8399624B1 (en) 2009-06-25 2013-03-19 Esbatech, An Alcon Biomedical Research Unit Llc Acceptor framework for CDR grafting
WO2011063277A1 (en) 2009-11-20 2011-05-26 Amgen Inc. Anti-orai1 antigen binding proteins and uses thereof
EP2619226B1 (en) 2010-09-22 2018-09-12 Amgen Inc. Carrier immunoglobulins and uses thereof
UY33679A (en) 2010-10-22 2012-03-30 Esbatech STABLE AND SOLUBLE ANTIBODIES
GB201310859D0 (en) * 2013-06-18 2013-07-31 Cambridge Entpr Ltd Rational method for solubilising proteins
WO2015032776A1 (en) * 2013-09-06 2015-03-12 F. Hoffmann-La Roche Ag Method for improving antibody stability
TW201620938A (en) 2014-09-15 2016-06-16 安美基公司 Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof
JP6932700B2 (en) 2015-09-15 2021-09-08 アムジエン・インコーポレーテツド Tetravalent bispecific antigen-binding proteins and tetravalent quadrispecific antigen-binding proteins, and their use
WO2017106578A1 (en) 2015-12-15 2017-06-22 Amgen Inc. Pacap antibodies and uses thereof
MA46753A (en) 2016-11-14 2019-09-18 Amgen Inc BISPECIFIC OR BIPARATOPIC ANTIGEN BINDING PROTEINS AND USES THEREOF
JOP20190248A1 (en) 2017-04-21 2019-10-20 Amgen Inc Trem2 antigen binding proteins and uses thereof
JP7339262B2 (en) 2018-01-12 2023-09-05 アムジェン インコーポレイテッド PAC1 antibody and uses thereof
US20210221915A1 (en) * 2018-06-08 2021-07-22 Ventana Medical Systems, Inc. Universal or normalized antibody frameworks for improved functionality and manufacturability
US20220235148A1 (en) 2019-05-30 2022-07-28 Amgen Inc. Engineering the hinge region to drive antibody dimerization
CA3143524A1 (en) 2019-06-28 2020-12-30 Amgen Inc. Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
AU2020380379A1 (en) 2019-11-08 2022-05-26 Amgen Inc. Engineering charge pair mutations for pairing of hetero-IgG molecules
CA3160438A1 (en) 2019-11-19 2021-05-27 Amgen Inc. Novel multispecific antibody format
UY38995A (en) 2019-12-20 2021-06-30 Amgen Inc MESOTHELIN TARGETING CD40 AGONIST MULTI-SPECIFIC ANTIBODY CONSTRUCTS FOR THE TREATMENT OF SOLID TUMORS
CA3191710A1 (en) 2020-08-20 2022-02-24 Amgen Inc. Antigen binding proteins with non-canonical disulfide in fab region
EP4225786A2 (en) 2020-10-07 2023-08-16 Amgen Inc. Rational selection of building blocks for the assembly of multispecific antibodies
CA3200603A1 (en) 2020-11-10 2022-05-19 Amgen Inc. Novel linkers of multispecific antigen binding domains
US20220259296A1 (en) 2021-02-12 2022-08-18 Boehringer Ingelheim International Gmbh Complement c3 antigen binding proteins
JP2024509910A (en) 2021-03-09 2024-03-05 シーディアール－ライフ・アクチェンゲゼルシャフト MAGE-A4 peptide-MHC antigen binding protein
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
EP4326761A1 (en) 2021-04-20 2024-02-28 Amgen Inc. Balanced charge distribution in electrostatic steering of chain pairing in multi-specific and monovalent igg molecule assembly
JP2024546875A (en) 2021-12-14 2024-12-26 シーディアール－ライフ・アクチェンゲゼルシャフト Dual MHC-targeted T cell engagers
PE20250390A1 (en) 2021-12-22 2025-02-11 Boehringer Ingelheim Int Anti-C3 antibodies and antigen-binding fragments thereof and their uses for treating ophthalmic or ocular diseases
CN120202015A (en) 2022-09-14 2025-06-24 Cdr-生物科技股份有限公司 MAGE-A4 peptide double T cell adaptors
WO2025210181A1 (en) 2024-04-04 2025-10-09 Cdr-Life Ag Antigen binding proteins targeting an hla-restricted kk-lc-1 peptide
US20250333514A1 (en) 2024-04-11 2025-10-30 Cdr-Life Ag Antigen binding proteins targeting an hla-restricted prame peptide

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
ATE139900T1 (en) * 1992-11-13 1996-07-15 Idec Pharma Corp THERAPEUTIC USE OF CHIMERIC AND LABELED ANTIBODIES AGAINST HUMAN B LYMPHOCYTE RESTRICTED DIFFERENTIATION ANTIGEN FOR THE TREATMENT OF B CELL LYMPHOMA
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6838254B1 (en) * 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
US6740734B1 (en) * 1994-01-14 2004-05-25 Biovitrum Ab Bacterial receptor structures
US6258562B1 (en) * 1996-02-09 2001-07-10 Basf Aktiengesellschaft Human antibodies that bind human TNFα
CN1062312C (en) * 1996-11-29 2001-02-21 中国科学院微生物研究所 Type 1V collagenase-resisting single stranded antibody
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
DE69839147T2 (en) * 1997-06-12 2009-02-19 Novartis International Pharmaceutical Ltd. ARTIFICIAL ANTIBODY POLYPEPTIDE
DE19742706B4 (en) 1997-09-26 2013-07-25 Pieris Proteolab Ag lipocalin muteins
EP1946775A3 (en) * 1998-08-11 2008-08-06 Biogen Idec Inc. Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
JP2002532159A (en) 1998-12-14 2002-10-02 オステオテック インコーポレーテッド Bone graft and guided bone regeneration
CN1232039A (en) * 1999-04-02 1999-10-20 中国人民解放军海军总医院 Genetic engineering double specific antibody and its use
US6602977B1 (en) * 1999-04-19 2003-08-05 Biovitrum Ab Receptor structures
SE9901379D0 (en) 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
CA2396534C (en) * 1999-12-28 2012-10-02 Esbatech Ag Intrabodies with defined framework that is stable in a reducing environment and applications thereof
ATE536375T1 (en) 2000-05-10 2011-12-15 Mayo Foundation HUMAN IGM ANTIBODIES WHICH HAVE THE ABILITY TO INDUCE THE RECONSTRUCTION OF MYELIN STRUCTURE AND THEIR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS IN THE CENTRAL NERVOUS SYSTEM
CA2421447C (en) 2000-09-08 2012-05-08 Universitat Zurich Collections of repeat proteins comprising repeat modules
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
WO2002088171A2 (en) 2001-04-26 2002-11-07 Avidia Research Institute Combinatorial libraries of monomer domains
CA2453662A1 (en) * 2001-07-19 2003-01-30 Stefan Ewert Modification of human variable domains
DK1506236T3 (en) 2002-05-22 2013-03-04 Esbatech A Novartis Co Llc IMMUNGLOBULIN FRAMEWORKS PROVIDING IMPROVED STABILITY IN THE INTRACELLULAR ENVIRONMENT AND PROCEDURES FOR IDENTIFICATION THEREOF
US20050033029A1 (en) * 2003-06-30 2005-02-10 Jin Lu Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
EP1658308A1 (en) 2003-08-25 2006-05-24 Pieris ProteoLab AG Muteins of a bilin-binding protein with affinity for a given target
BRPI0417023A (en) 2003-11-28 2007-02-21 Astrazeneca Ab human antibody or antibody fragment, use thereof, pharmaceutical composition, methods for treating a patient suffering from an amyloid disorder, for diagnosing an amyloid disorder in a patient, and for detecting the presence of apoe-ctd in a patient sample polynucleotide vector host cell virus and apoe-ctd detection kit
JP2008500064A (en) 2004-05-21 2008-01-10 ザ ユーエービー リサーチ ファウンデーション Variable lymphocyte receptor, related polypeptides and nucleic acids, and uses thereof
GB0416651D0 (en) 2004-07-26 2004-08-25 Proteo Target Aps Polypeptide
BRPI0518151A2 (en) * 2004-10-13 2009-06-16 Ablynx Nv polypeptides against amyloid-beta, nucleic acid encoding such polypeptide, composition comprising such polypeptide, method for producing a polypeptide and use thereof
US7462697B2 (en) * 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
EP3260465A1 (en) 2005-06-07 2017-12-27 ESBATech, an Alcon Biomedical Research Unit LLC Stable and soluble antibodies inhibiting tnf-alpha
SI1963368T1 (en) 2005-12-13 2012-11-30 Lilly Co Eli Anti-il-17 antibodies
DK2046382T3 (en) 2006-07-10 2016-12-12 Esbatech Alcon Biomed Res Unit scFv Antibodies which passes through the epithelial and / or endothelial layer
IN2009DN05758A (en) 2007-03-12 2015-07-24 Esbatech Ag
RU2010102064A (en) * 2007-06-25 2011-07-27 Эсбатек, Эн Элкон Биомедикал Рисёрч Юнит Ллк (Ch) METHOD OF DESIGNING BASED ON DETERMINATION OF SEQUENCES, METHOD OF OPTIMIZATION OF SINGLE-CHAIN ANTIBODIES
NZ581468A (en) 2007-06-25 2012-09-28 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies, and modified antibodies with improved functional properties

Also Published As

Publication number Publication date
HK1138602A1 (en) 2010-08-27
CN101668771A (en) 2010-03-10
JP5622397B2 (en) 2014-11-12
US20100137150A1 (en) 2010-06-03
US8280711B2 (en) 2012-10-02
IL200710A (en) 2014-07-31
US9938336B2 (en) 2018-04-10
RU2009137582A (en) 2011-04-20
AU2008226067A1 (en) 2008-09-18
NZ579594A (en) 2012-03-30
CN103275216A (en) 2013-09-04
CN103275216B (en) 2015-05-06
EP3202786A3 (en) 2017-10-11
IL200710A0 (en) 2010-05-17
US20130053259A1 (en) 2013-02-28
EP3202786A2 (en) 2017-08-09
JP2010523077A (en) 2010-07-15
AU2008226067B2 (en) 2012-11-08
WO2008110348A1 (en) 2008-09-18
CA2680564A1 (en) 2008-09-18
RU2014127308A (en) 2016-02-10
CA2680564C (en) 2018-05-01
CN101668771B (en) 2013-08-21
EP2118138A1 (en) 2009-11-18

Similar Documents

Publication Publication Date Title
IN2009DN05758A (en)
MX2009013327A (en) Sequence based engineering and optimization of single chain antibodies.
MX2009013328A (en) Methods of modifying antibodies, and modified antibodies with improved functional properties.
WO2021018859A3 (en) Antibodies binding to gprc5d
DK1629011T3 (en) Human anti-human DC3 binding molecules
AR095980A1 (en) SPECIFIC BIESPECTIFIC ANTIBODIES FOR FAP (FIBROBLASTIC ACTIVATION PROTEIN) AND DR5 (DEATH RECEIVER 5), SPECIFIC ANTIBODIES FOR DR5 AND METHODS OF USE
IN2014MN00873A (en)
EA201390146A1 (en) ANTIBODIES TO MATRIX METALLOPROTEINASE 9
TN2014000120A1 (en) Cd27l antigen binding proteins
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
PH12015501505A1 (en) Antibodies that bind to tl1a and their uses
NZ706377A (en) Il-6 antagonists and uses thereof
DE602006013029D1 (en) ANTI-EGFR ANTIBODY
DOP2011000232A (en) PROTEINS OF UNION TO IL-1
CO6231038A2 (en) UNION PROTEINS, INCLUDING ANTIBODIES DERIVED FROM ANTIBODY AND ANTIBODY FRAGMENTS THAT SPECIFICALLY JOIN CD154 AND ITS USES
MX2018007630A (en) Antibodies to matrix metalloproteinase 9.
ATE431423T1 (en) METHOD FOR SCREENING THE LIGHT CHAIN OF AN ANTIBODY
UA95068C2 (en) Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
NO20092285L (en) Human monoclonal antibodies to BTLA and methods of use
UA94576C2 (en) Isolated antibody that binds to igf-1r, composition and methods relating to anti-igf-1 receptor antibodies
ES2639026T3 (en) Totally human antibodies specific for CADM1
NZ720765A (en) Antibodies and methods of use
MXPA06010715A (en) Human anti-epidermal growth factor receptor antibody.
UA106070C2 (en) Antibody that specifically binds to egfr and her3